<?xml version="1.0" encoding="UTF-8"?>
<ref id="ref61">
 <mixed-citation publication-type="book">
  <person-group person-group-type="author">
   <name>
    <surname>Hanfelt-Goade</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Maimon</surname>
    <given-names>N.</given-names>
   </name>
   <name>
    <surname>Nimer</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Riviere</surname>
    <given-names>F.</given-names>
   </name>
   <name>
    <surname>Catherinot</surname>
    <given-names>E.</given-names>
   </name>
   <name>
    <surname>Ison</surname>
    <given-names>M.</given-names>
   </name>
   <etal/>
  </person-group> (
  <year>2018</year>). “
  <article-title>A phase 2b, randomized, double-blind, placebo-controlled trial of Presatovir (GS-5806), a novel Oral RSV fusion inhibitor, for the treatment of respiratory syncytial virus (RSV) in hospitalized adults</article-title>” in 
  <source>C17. New insights in acute pulmonary infections</source> (
  <publisher-loc>San Diego, CA</publisher-loc>: 
  <publisher-name>American Thoracic Society</publisher-name>), 
  <fpage>A4457</fpage>–
  <lpage>A4457</lpage>.
 </mixed-citation>
</ref>
